Koyfin Home > Directory > Health Care > Arbutus Biopharma Cp > Long-Term Debt

Arbutus Biopharma Cp Long-Term Debt Chart (ABUS)

Arbutus Biopharma Cp annual/quarterly Long-Term Debt from 2016 to 2017.
  • Arbutus Biopharma Cp Long-Term Debt for the quarter ending December 12, 2017 was $12m a -0.01% decrease of 0m year over year
  • Arbutus Biopharma Cp Long-Term Debt for the last 12 months ending December 12, 2017 was $12m a -0.01% decrease of 0m year over year
  • Arbutus Biopharma Cp Annual Long-Term Debt for 2017 was $12m a -0.01% decrease of 0m from 2016
  • Arbutus Biopharma Cp Annual Long-Term Debt for 2016 was $12m
Other Cash Flow Metrics:
  • Arbutus Biopharma Cp Cash Flow from Operations for the quarter ending December 12, 2018 was $-17m a -16.70% increase of 3m year over year
  • Arbutus Biopharma Cp Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-36m a 63.34% decrease of -23m year over year
  • Arbutus Biopharma Cp Total Revenue for the quarter ending December 12, 2018 was $2m a 12.06% increase of 0m year over year
View Chart On Koyfin

Quarterly ABUS Long-Term Debt Data

12/2017$12m
09/2017$12m
06/2017$12m
03/2017$12m
12/2016$12m

Annual ABUS Long-Term Debt Data

2017$12m
2016$12m